Loading clinical trials...
Loading clinical trials...
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Conditions
Interventions
Abemaciclib
Standard Adjuvant ET
+1 more
Locations
115
United States
Palo Verde Cancer Specialists
Glendale, Arizona, United States
TRIO-US (Translational Research in Oncology-US)
Los Angeles, California, United States
Millennium Oncology - Hollywood
Hollywood, Florida, United States
Florida Cancer Specialists - North
St. Petersburg, Florida, United States
Mt. Sinai Hospital PRiSMS
Chicago, Illinois, United States
Cornell-Beshore Cancer Institute
Joplin, Missouri, United States
Start Date
May 10, 2021
Primary Completion Date
June 26, 2024
Completion Date
June 26, 2024
Last Updated
July 15, 2025
NCT06608446
NCT04389632
NCT07174336
NCT06966700
NCT04895709
NCT05386108
Lead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions